Regulators in Europe have said that blood clots “should be listed as very rare side effects” of the Oxford/AstraZeneca vaccine.
Some European countries have restricted use of the jab in younger people following reports of cerebral venous sinus thrombosis.
This is a type of clot that prevents blood from draining from the brain, as well as low platelet counts – cells that help blood clot.
The European Medicines Agency (EMA) said today a safety committee review has concluded that “unusual blood clots with low blood platelets should be listed as very rare side effects” of the Oxford/AstraZeneca vaccine.
The Medicines and Healthcare products Regulatory Agency (MHRA) – Britain’s regulator – is also providing an update simultaneously this afternoon.
“One plausible explanation for the combination of blood clots and low blood platelets is an immune response, leading to a condition similar to one seen sometimes in patients treated with heparin,” the EMA said.